Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years. - Wikidata - awgldk - TriplyDB

Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years.

Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years.

http://www.wikidata.org/entity/Q40891715

about

Real-World Effectiveness and Safety of a Live-Attenuated Herpes Zoster Vaccine: A Comprehensive Review The Glycoprotein B Cytoplasmic Domain Lysine Cluster Is Critical for Varicella-Zoster Virus Cell-Cell Fusion Regulation and Infection Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.Temporal trends in herpes zoster-related hospitalizations in Italy, 2001-2013: differences between regions that have or have not implemented varicella vaccination.Role for the αV Integrin Subunit in Varicella-Zoster Virus-Mediated Fusion and Infection.Effectiveness and Duration of Protection Provided by the Live-attenuated Herpes Zoster Vaccine in the Medicare Population Ages 65 Years and Older.Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases.Herpes zoster - typical and atypical presentations.Vaccine profile of herpes zoster (HZ/su) subunit vaccine.Clinical and economic impact of herpes zoster vaccination in elderly in Italy.Clinical Usage of the Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su): Revaccination of Recipients of Live Attenuated Zoster Vaccine and Coadministration With a Seasonal Influenza Vaccine.Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.Studies with herpes zoster vaccines in immune compromised patients.Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults.Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study.Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany : Statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute (RKI)Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study.Herpes Zoster Vaccine: Time for a Boost?Effectiveness of herpes zoster vaccination in an older United Kingdom population.Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged ≥50 Years.The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50 Years in Japan: Results of a Markov Model Analysis.A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profile The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis Herpes Zoster DNA Vaccines with IL-7 and IL-33 Molecular Adjuvants Elicit Protective T Cell Immunity

P2860

Q26748712-53189451-5BA0-40F5-B129-42361F5E3AA0 Q37512919-F647E905-47F1-4933-B575-CC8A764A4D54 Q38678770-AD2DCD56-45E3-42F7-A2DB-19F11CABD3DB Q38728383-6E0D854A-CC3D-4EA9-AFEF-BDA26EEE1175 Q38765572-2C06522D-5F8B-4BF2-8952-14945EBC7B13 Q38864559-CDBC802F-7767-4DD5-8B51-33B5883AE1B6 Q38905074-26F4A943-66C7-45C5-A5B1-146BA6D92987 Q40187065-CEC93CC0-BC2B-42BF-8959-8DBAA7BD2B76 Q40208840-8CF70AE5-B435-4328-90BE-EE86CFC2493E Q45937750-5DD8E723-4CFB-4800-AE73-B221C58E1E28 Q46046365-604C87C0-E7BD-47E5-8ED9-85F6896B972F Q46892547-E74AFF12-4727-48DC-AD2A-1D9066C6972A Q47605669-728BD774-5BD9-44AD-846E-A099F22881FF Q49693513-06ED78D0-BB23-41E0-A60B-D31B6999F457 Q50105407-5A2A272C-06E8-4300-97D5-CE577605738D Q50115825-03B2CD65-1DCE-4027-9308-B0644E3774FE Q50210244-D1957224-67DD-4CB4-A0B6-8E2BB628AE97 Q51770045-2608248D-9BBE-4CB0-B8C2-5F9EA178540C Q51774491-DE6493F5-618C-4C75-A2B0-63A69BC815CC Q52648252-C9ACDE23-3332-4F00-81BB-F127585B3369 Q52727148-142EC8CB-6E54-49B0-A5A4-F37D8AF1CABB Q54230925-961244D1-DBAC-4CDB-82E3-B6645BD2A9F0 Q56888201-D9D8C5EF-F4B1-47A4-B7AD-9193543E3439 Q57395637-D420AF58-B6F4-44DA-8757-D97D1207AD06 Q58553251-55183BE8-A9BD-4D08-8C8F-113AA6B193C2 Q58584452-F22214F3-F85E-4E32-9320-7E939FEB5436

P2860

Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years.

http://www.wikidata.org/entity/Q40891715

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years.

@en

type

label

Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years.

@en

prefLabel

Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years.

@en

P1433

Q40891715-1D63B241-3C7D-48C8-8186-A8D01B58BD94

P1476

Q40891715-F85BFDF5-570D-4770-9A24-0AA25159BC9E

P2093

Q40891715-08D9D8B2-6462-454E-A0DF-0D1BC748C8B1

Q40891715-3DC55B91-71D7-49C8-996D-1E3CCDDD82A7

Q40891715-5A7C63D1-C8FD-44D4-B8A1-F60836ED7ECE

Q40891715-66392DAA-C4AE-4BB1-BC9F-1B91D4FF9409

Q40891715-6FFA91BA-A956-4920-BF92-BCBC1988D644

Q40891715-8DE45FB9-AEC5-43DC-857E-86CF68645918

Q40891715-92109F25-C776-4F30-A77A-52E974B70D8D

Q40891715-B12F39C0-5241-4C9E-B143-E5E61B633040

Q40891715-B9925299-B221-409B-B610-123BE472247F

P2860

Q40891715-05DF6394-B826-487E-9246-924C45691D39

Q40891715-1CDFBD0A-A17B-45BE-8A9A-C42A67EC23F0

Q40891715-238DCE6A-A94F-402E-8AF4-E62B96A30C2E

Q40891715-348439F0-C990-4518-91A3-7C7279D40194

Q40891715-4383A560-2783-4872-8731-CAEDB8DF95DC

Q40891715-5CC1FC7E-63E2-483A-9F59-B43FB516BD29

Q40891715-746705BD-D328-4873-A0DF-268CA63F9E0E

Q40891715-900BD016-1689-4490-88DC-8D7AB8F7B97B

Q40891715-D0A932EF-65D9-4D70-BC54-316D36BEB813

Q40891715-EB3614FB-DA32-445D-8A41-915180DEDDCD

P304

Q40891715-02510B90-9E7A-4E28-9758-A6F4F29878DA

P31

Q40891715-DF5D7E3E-2D56-418C-8EBA-925C13DECC5B

P356

Q40891715-2FC4B19D-B6C0-4DCC-96CD-B2F33FB18D96

P407

Q40891715-0BB7B997-AB3C-4010-B4D2-C7CB6194CBFD

P433

Q40891715-E6717E4F-B786-4AD0-A45E-AFFC8500A596

P478

Q40891715-091595E5-7B16-4E01-9FD6-9F6720BC2D3C

P577

Q40891715-E77CE026-3C48-411D-B733-3093F1908FBA

P698

Q40891715-5A030C51-5173-46EC-9643-93989A2D5D89

P356

P1433

The Journal of Infectious Diseases

P1476

Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years.

@en

P2093

Craig M Hales

http://www.w3.org/2001/XMLSchema#string

Hung Fu Tseng

http://www.w3.org/2001/XMLSchema#string

Lina S Sy

http://www.w3.org/2001/XMLSchema#string

Rafael Harpaz

http://www.w3.org/2001/XMLSchema#string

Rulin C Hechter

http://www.w3.org/2001/XMLSchema#string

Sara Y Tartof

http://www.w3.org/2001/XMLSchema#string

Stephanie Bialek

http://www.w3.org/2001/XMLSchema#string

Steven J Jacobsen

http://www.w3.org/2001/XMLSchema#string

Yi Luo

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

Incidence of Herpes Zoster, Before and After Varicella‐Vaccination–Associated Decreases in the Incidence of Varicella, 1992–2002

Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data.

Race and ethnicity data quality and imputation using U.S. Census data in an integrated health system: the Kaiser Permanente Southern California experience.

Long-term persistence of zoster vaccine efficacy

Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy.

Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

P304

1872-1875

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIW047

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

213

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26908728

http://www.w3.org/2001/XMLSchema#string